-
An investigation of the efficacy of polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom.
Bradley, A.; Journal of Dairy Sci., Jan 2015.
Analysis of milk production data after the use of a commercially available vaccine against mastitis, demonstrated a return on investment of 2.6 to 1 based on milk yield alone.
-
Efficacy of vaccination on Staphylococcus aureus and coagulase-negative staphylococci intramammary infection dynamics in 2 dairy herds.
Schukken, Y.; Journal of Dairy Sci. 97:1–15, 2014.
A large field study (40,000 samples) concludes that vaccination was a valuable tool in reducing incidence and prevalence of staphylococcal infections and is able to reduce to half the basic reproduction ratio. -
Mastitis control: the use of a vaccine.
Torres, E.; NMC, 2014.
Evaluate the effectiveness of two different vaccination protocols against bovine mastitis during lactation (STARTVAC®, HIPRA).
-
STARTVAC® Vaccination against mastitis: estimation of efficacy in dairy herds and immunological response.
Piepers, S.; Buistrissima 2013.
Lower incidence of S.aureus and reduction of the duration of infection (preliminary results). After a challenge there was no decrease of the milk produccion in vaccined cows and the level of antibodies Anti-SAAC and Anti-J5 in milk and blood were higher. -
Assessment of the use of STARTVAC® vaccine on a dairy farm affected by environmental mastitis.
Ribeiro, C.; STARTVAC® Library 2013.
Reduction of intramammary antibiotic treatment costs and decrease of BTSCC from 446.000 to 239.000. -
Case study, use of vaccination to control bovine mastitis caused by Staphylococcus aureus.
Ortega, R.; NMC 2013.
Increase of cure rate after dry-off with vaccination classic protocol, decrease of S. aureus prevalence 30% to 1,26%, BTSCC decrease and reduction in treatment costs in 50%. -
The role of vaccination in Coliform mastitis control.
Bradley, A.; U. Ghent 2013.
Increase of milk production, decrease of mastitis severity (no culling for toxic mastitis). -
Case study, udder health in heifers after vaccination against mastitis.
Roger, N.; NMC 2013.
Reduction in SCC average, reduction of infection prevalence and new infections including new fresh infections, after calving, decrease in clinical mastitis cases per month and increase of milk production. -
Case study, association between vaccination and dairy mastitis on a UK dairy farm.
Lindsay, C.; NMC 2013.
Reduction of SCC herd average, reduction of culling rate and clinical mastitis, reduction of duration of extended therapy , decrease of new infections and repeated cases. -
STARTVAC® vaccination against bovine mastitis on dairy herd in central Ukraine.
Nikolayevich, G. V.; WBC 2012.
Reduction in clinical mastitis (6% to 2%), reduction in animal losses 3-5 to 1 per month, clearance of isolates of S. aureus, less use of antibiotics (reduction in 55-60%), increase in cure rate and BTSCC 257.000 to 163.000. -
Inmunological response to an experimental intrammamary inoculation with a killed Staphylococcus aureus strain in vaccinated and non-vaccinated lactating dairy cows.
Piepers, S.; WBC 2012.
Vaccinated cows less severe inflamatory response, more milk production, antibodies anti-S. aureus and anti-E. coli.in serum and in milk. -
Inmunological response to an experimental intrammamary inoculation with a killed Staphylococcus aureus strain in vaccinated and non-vaccinated lactating dairy cows (Proceedings).
Piepers, S.; WBC 2012.
Vaccinated cows less severe inflamatory response, more milk production, antibodies anti-S. aureus and anti-E. coli in serum and in milk.
-
Field study, use of STARTVAC® bovine mastitis vaccine on a swedish dairy farm.
Amroth, C.; WBC 2012.
Decrease BTSCC from 128.000 to 243.000, decrease in clinical and subclinical mastitis from 11,7% to 4,4%, decrease prevalence in CNS from 13,9% to 7,8%, E. coli slight decrease. -
Field study, control of intrammamary infection and somatic cell count using the STARTVAC® vaccine.
Carvajal, A.; WBC 2012.
Reduction in individual somatic cell count 45 days after calving in primiparus and multiparous. -
Estimation of efficacy of STARTVAC® vaccination.
Schukken, Y.; WBC 2012.
Efficacy in reduce new infections 57% and in reduce duration of infection 70%, about 30 days less of infection period in vaccinated animals. -
Experience of STARTVAC® use on a dairy farm in southern Ukraine.
Kumanovsky, A.; WBC 2012.
BTSCC decrease from 436.000 to 96.000, reduction of clinical mastitis from 7 to 2 and increase in milk porduction by 0,8 kg. -
Evaluation of the efficacy of a new vaccine against bovine mastitis caused by CNS, field trial results.
Noguera, M.; UHC 2011.
Reduction in the incidence of the intramammary infections caused by CNS 2,6% vs 5,9%, biofilm production was detected in 37% of CNS in the control group and 31% in the vaccinated. -
Efficacy of the vaccine STARTVAC® in an australian dairy herd.
Hofer, J.; EBF 2011.
Reduction in S. aureus isolates from 58 to low level, decrease in individual SCC and BTSCC. -
Vaccination as a tool to prevent intrammamary infection field study.
Jimenez, L. M.; EBF 2011.
Reduction of new infection rate, reduction of clinical mastitis cases and increase in milk production. -
Efficacy of vaccination on mastitis epidemiology, field study.
Jimenez, L. M.; NMC 2010.
Reduction of new infection rate 8 vs 16 in cows and 6,2% vs 24,1% in primiparous, reduction of S. aureus isolates, increase of number of E. coli isolates, reduction in clincial mastitis 30% vs 43,2% in cows and 3,4% vs 13,3% in primiparous. -
Follow-up of farm use of a vaccine against staphylococcus and coliform mastitis (STARTVAC®, HIPRA).
Serieys, F.; SNGTV 2010.
Reduction of more than 25%somatic cell counts in multiparous cows, i.e. approximately 100,000 fewer cells/ml (P<0.05), and in nearly 30% fewer antibiotic treatments during lactation (P<0.05). -
Efficacy evaluation of a new vaccine against bovine mastitis, field trial results.
March, R.; NMC 2010.
Less clinical and subclinical mastitis, less severity in clinical mastitis (SCC, milk aspect, mamary gland aspect, mastitis treatments). -
Efficacy of an Escherichia coli J5 Mastitis vaccine in an experimental challenge trial.
Foix, A.; NMC 2009.
Challenge E. coli, reduction in the severity e.g. drop in milk and clinical signs, positive effect on bacterial clearance and SCC. -
Study of the humoral inmunological response after vaccination with a staphyloccus aureus biofilm-embedded bacterin in dairy cows.
Prenafeta, A.; NMC 2009.
Inmunization with S. aureus bacterin with high SAAC was able to reduce S. aureus multiplication and enhances antibody titers against SAAC.